On January 6, 2021 AbbVie (NYSE: ABBV) reported that it will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 (Press release, AbbVie, JAN 6, 2021, View Source [SID1234573538]). Members of AbbVie’s executive leadership team will present virtually at 3:30 p.m. Central time, including Richard A. Gonzalez, chairman of the board and chief executive officer, Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

On January 6, 2021 IMMUNOPRECISE ANTIBODIES LTD. ("IPA") (Nasdaq: IPA) (TSXV: IPA) a leader in full-service, therapeutic antibody discovery, reported that Dr. Jennifer Bath, ImmunoPrecise’s Chief Executive Officer, will participate in a pre-recorded presentation through the H.C. Wainwright BioConnect 2021 Conference, and management will host one-on-one meetings with investors through the Stern IR Virtual Corporate Access Event, both taking place January 11-14, 2021 (Press release, ImmunoPrecise Antibodies, JAN 6, 2021, View Source [SID1234573536]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The H.C. Wainwright presentation will be available for on-demand viewing beginning Monday, January 11, 2021 at 6:00 a.m. ET. The recording can be accessed via H.C. Wainwright Bioconnect website at and will be available for approximately 30 days.

On January 6, 2021 Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, reported that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright Virtual BioConnect Conference being held from January 11-14, 2021 (Press release, Anavex Life Sciences, JAN 6, 2021, https://www.anavex.com/anavex-life-sciences-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference/ [SID1234573534]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the on-demand presentation will be available beginning Monday, January 11, 2021 on the Company’s website at www.anavex.com.

On January 6, 2021 Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, reported that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually on Tuesday, January 12, 2021 at 5:20 PM ET (Press release, Replimune, JAN 6, 2021, View Source [SID1234573531]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for 30 days following the conference.

On January 6, 2021, Immatics N.V. (the "Company") presented the Corporate Presentation (Presentation, Immatics, JAN 6, 2021, View Source [SID1234573530]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!